Global Performance Enhancing Drugs Market Growth 2025-2031

October 2025 | 101 pages | ID: G963E389AF49EN
LP Information

Abstracts

The global Performance Enhancing Drugs market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Performance-enhancing drugs (PED), are substances that are used to improve any form of activity performance in humans.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the ?Performance Enhancing Drugs Industry Forecast? looks at past sales and reviews total world Performance Enhancing Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Performance Enhancing Drugs sales for 2025 through 2031. With Performance Enhancing Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Performance Enhancing Drugs industry.

This Insight Report provides a comprehensive analysis of the global Performance Enhancing Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Performance Enhancing Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Performance Enhancing Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Performance Enhancing Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Performance Enhancing Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Performance Enhancing Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Pills
• Injections
• Patches

Segmentation by Application:

• Athletes
• Students
• Militaries
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Taj Pharmaceuticals
• Balkan Pharmaceuticals
• Bayer
• AstraZeneca
• Novo Nordisk
• BrainAlert
• Douglas Laboratories
• Onnit Labs
• Eli Lilly And Company

Key Questions Addressed in this Report

What is the 10-year outlook for the global Performance Enhancing Drugs market?
What factors are driving Performance Enhancing Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Performance Enhancing Drugs market opportunities vary by end market size?
How does Performance Enhancing Drugs break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Performance Enhancing Drugs Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Performance Enhancing Drugs by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Performance Enhancing Drugs by Country/Region, 2020, 2024 & 2031
2.2 Performance Enhancing Drugs Segment by Type
  2.2.1 Pills
  2.2.2 Injections
  2.2.3 Patches
2.3 Performance Enhancing Drugs Sales by Type
  2.3.1 Global Performance Enhancing Drugs Sales Market Share by Type (2020-2025)
  2.3.2 Global Performance Enhancing Drugs Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Performance Enhancing Drugs Sale Price by Type (2020-2025)
2.4 Performance Enhancing Drugs Segment by Application
  2.4.1 Athletes
  2.4.2 Students
  2.4.3 Militaries
  2.4.4 Others
2.5 Performance Enhancing Drugs Sales by Application
  2.5.1 Global Performance Enhancing Drugs Sale Market Share by Application (2020-2025)
  2.5.2 Global Performance Enhancing Drugs Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Performance Enhancing Drugs Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Performance Enhancing Drugs Breakdown Data by Company
  3.1.1 Global Performance Enhancing Drugs Annual Sales by Company (2020-2025)
  3.1.2 Global Performance Enhancing Drugs Sales Market Share by Company (2020-2025)
3.2 Global Performance Enhancing Drugs Annual Revenue by Company (2020-2025)
  3.2.1 Global Performance Enhancing Drugs Revenue by Company (2020-2025)
  3.2.2 Global Performance Enhancing Drugs Revenue Market Share by Company (2020-2025)
3.3 Global Performance Enhancing Drugs Sale Price by Company
3.4 Key Manufacturers Performance Enhancing Drugs Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Performance Enhancing Drugs Product Location Distribution
  3.4.2 Players Performance Enhancing Drugs Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR PERFORMANCE ENHANCING DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Performance Enhancing Drugs Market Size by Geographic Region (2020-2025)
  4.1.1 Global Performance Enhancing Drugs Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Performance Enhancing Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Performance Enhancing Drugs Market Size by Country/Region (2020-2025)
  4.2.1 Global Performance Enhancing Drugs Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Performance Enhancing Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Performance Enhancing Drugs Sales Growth
4.4 APAC Performance Enhancing Drugs Sales Growth
4.5 Europe Performance Enhancing Drugs Sales Growth
4.6 Middle East & Africa Performance Enhancing Drugs Sales Growth

5 AMERICAS

5.1 Americas Performance Enhancing Drugs Sales by Country
  5.1.1 Americas Performance Enhancing Drugs Sales by Country (2020-2025)
  5.1.2 Americas Performance Enhancing Drugs Revenue by Country (2020-2025)
5.2 Americas Performance Enhancing Drugs Sales by Type (2020-2025)
5.3 Americas Performance Enhancing Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Performance Enhancing Drugs Sales by Region
  6.1.1 APAC Performance Enhancing Drugs Sales by Region (2020-2025)
  6.1.2 APAC Performance Enhancing Drugs Revenue by Region (2020-2025)
6.2 APAC Performance Enhancing Drugs Sales by Type (2020-2025)
6.3 APAC Performance Enhancing Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Performance Enhancing Drugs by Country
  7.1.1 Europe Performance Enhancing Drugs Sales by Country (2020-2025)
  7.1.2 Europe Performance Enhancing Drugs Revenue by Country (2020-2025)
7.2 Europe Performance Enhancing Drugs Sales by Type (2020-2025)
7.3 Europe Performance Enhancing Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Performance Enhancing Drugs by Country
  8.1.1 Middle East & Africa Performance Enhancing Drugs Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Performance Enhancing Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Performance Enhancing Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Performance Enhancing Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Performance Enhancing Drugs
10.3 Manufacturing Process Analysis of Performance Enhancing Drugs
10.4 Industry Chain Structure of Performance Enhancing Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Performance Enhancing Drugs Distributors
11.3 Performance Enhancing Drugs Customer

12 WORLD FORECAST REVIEW FOR PERFORMANCE ENHANCING DRUGS BY GEOGRAPHIC REGION

12.1 Global Performance Enhancing Drugs Market Size Forecast by Region
  12.1.1 Global Performance Enhancing Drugs Forecast by Region (2026-2031)
  12.1.2 Global Performance Enhancing Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Performance Enhancing Drugs Forecast by Type (2026-2031)
12.7 Global Performance Enhancing Drugs Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Taj Pharmaceuticals
  13.1.1 Taj Pharmaceuticals Company Information
  13.1.2 Taj Pharmaceuticals Performance Enhancing Drugs Product Portfolios and Specifications
  13.1.3 Taj Pharmaceuticals Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Taj Pharmaceuticals Main Business Overview
  13.1.5 Taj Pharmaceuticals Latest Developments
13.2 Balkan Pharmaceuticals
  13.2.1 Balkan Pharmaceuticals Company Information
  13.2.2 Balkan Pharmaceuticals Performance Enhancing Drugs Product Portfolios and Specifications
  13.2.3 Balkan Pharmaceuticals Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 Balkan Pharmaceuticals Main Business Overview
  13.2.5 Balkan Pharmaceuticals Latest Developments
13.3 Bayer
  13.3.1 Bayer Company Information
  13.3.2 Bayer Performance Enhancing Drugs Product Portfolios and Specifications
  13.3.3 Bayer Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 Bayer Main Business Overview
  13.3.5 Bayer Latest Developments
13.4 AstraZeneca
  13.4.1 AstraZeneca Company Information
  13.4.2 AstraZeneca Performance Enhancing Drugs Product Portfolios and Specifications
  13.4.3 AstraZeneca Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 AstraZeneca Main Business Overview
  13.4.5 AstraZeneca Latest Developments
13.5 Novo Nordisk
  13.5.1 Novo Nordisk Company Information
  13.5.2 Novo Nordisk Performance Enhancing Drugs Product Portfolios and Specifications
  13.5.3 Novo Nordisk Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 Novo Nordisk Main Business Overview
  13.5.5 Novo Nordisk Latest Developments
13.6 BrainAlert
  13.6.1 BrainAlert Company Information
  13.6.2 BrainAlert Performance Enhancing Drugs Product Portfolios and Specifications
  13.6.3 BrainAlert Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 BrainAlert Main Business Overview
  13.6.5 BrainAlert Latest Developments
13.7 Douglas Laboratories
  13.7.1 Douglas Laboratories Company Information
  13.7.2 Douglas Laboratories Performance Enhancing Drugs Product Portfolios and Specifications
  13.7.3 Douglas Laboratories Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.7.4 Douglas Laboratories Main Business Overview
  13.7.5 Douglas Laboratories Latest Developments
13.8 Onnit Labs
  13.8.1 Onnit Labs Company Information
  13.8.2 Onnit Labs Performance Enhancing Drugs Product Portfolios and Specifications
  13.8.3 Onnit Labs Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.8.4 Onnit Labs Main Business Overview
  13.8.5 Onnit Labs Latest Developments
13.9 Eli Lilly And Company
  13.9.1 Eli Lilly And Company Company Information
  13.9.2 Eli Lilly And Company Performance Enhancing Drugs Product Portfolios and Specifications
  13.9.3 Eli Lilly And Company Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.9.4 Eli Lilly And Company Main Business Overview
  13.9.5 Eli Lilly And Company Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Performance Enhancing Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Performance Enhancing Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Pills
Table 4. Major Players of Injections
Table 5. Major Players of Patches
Table 6. Global Performance Enhancing Drugs Sales by Type (2020-2025) & (K Units)
Table 7. Global Performance Enhancing Drugs Sales Market Share by Type (2020-2025)
Table 8. Global Performance Enhancing Drugs Revenue by Type (2020-2025) & ($ million)
Table 9. Global Performance Enhancing Drugs Revenue Market Share by Type (2020-2025)
Table 10. Global Performance Enhancing Drugs Sale Price by Type (2020-2025) & (USD/Unit)
Table 11. Global Performance Enhancing Drugs Sale by Application (2020-2025) & (K Units)
Table 12. Global Performance Enhancing Drugs Sale Market Share by Application (2020-2025)
Table 13. Global Performance Enhancing Drugs Revenue by Application (2020-2025) & ($ million)
Table 14. Global Performance Enhancing Drugs Revenue Market Share by Application (2020-2025)
Table 15. Global Performance Enhancing Drugs Sale Price by Application (2020-2025) & (USD/Unit)
Table 16. Global Performance Enhancing Drugs Sales by Company (2020-2025) & (K Units)
Table 17. Global Performance Enhancing Drugs Sales Market Share by Company (2020-2025)
Table 18. Global Performance Enhancing Drugs Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Performance Enhancing Drugs Revenue Market Share by Company (2020-2025)
Table 20. Global Performance Enhancing Drugs Sale Price by Company (2020-2025) & (USD/Unit)
Table 21. Key Manufacturers Performance Enhancing Drugs Producing Area Distribution and Sales Area
Table 22. Players Performance Enhancing Drugs Products Offered
Table 23. Performance Enhancing Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Performance Enhancing Drugs Sales by Geographic Region (2020-2025) & (K Units)
Table 27. Global Performance Enhancing Drugs Sales Market Share Geographic Region (2020-2025)
Table 28. Global Performance Enhancing Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Performance Enhancing Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Performance Enhancing Drugs Sales by Country/Region (2020-2025) & (K Units)
Table 31. Global Performance Enhancing Drugs Sales Market Share by Country/Region (2020-2025)
Table 32. Global Performance Enhancing Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Performance Enhancing Drugs Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Performance Enhancing Drugs Sales by Country (2020-2025) & (K Units)
Table 35. Americas Performance Enhancing Drugs Sales Market Share by Country (2020-2025)
Table 36. Americas Performance Enhancing Drugs Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Performance Enhancing Drugs Sales by Type (2020-2025) & (K Units)
Table 38. Americas Performance Enhancing Drugs Sales by Application (2020-2025) & (K Units)
Table 39. APAC Performance Enhancing Drugs Sales by Region (2020-2025) & (K Units)
Table 40. APAC Performance Enhancing Drugs Sales Market Share by Region (2020-2025)
Table 41. APAC Performance Enhancing Drugs Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Performance Enhancing Drugs Sales by Type (2020-2025) & (K Units)
Table 43. APAC Performance Enhancing Drugs Sales by Application (2020-2025) & (K Units)
Table 44. Europe Performance Enhancing Drugs Sales by Country (2020-2025) & (K Units)
Table 45. Europe Performance Enhancing Drugs Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Performance Enhancing Drugs Sales by Type (2020-2025) & (K Units)
Table 47. Europe Performance Enhancing Drugs Sales by Application (2020-2025) & (K Units)
Table 48. Middle East & Africa Performance Enhancing Drugs Sales by Country (2020-2025) & (K Units)
Table 49. Middle East & Africa Performance Enhancing Drugs Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Performance Enhancing Drugs Sales by Type (2020-2025) & (K Units)
Table 51. Middle East & Africa Performance Enhancing Drugs Sales by Application (2020-2025) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Performance Enhancing Drugs
Table 53. Key Market Challenges & Risks of Performance Enhancing Drugs
Table 54. Key Industry Trends of Performance Enhancing Drugs
Table 55. Performance Enhancing Drugs Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Performance Enhancing Drugs Distributors List
Table 58. Performance Enhancing Drugs Customer List
Table 59. Global Performance Enhancing Drugs Sales Forecast by Region (2026-2031) & (K Units)
Table 60. Global Performance Enhancing Drugs Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas Performance Enhancing Drugs Sales Forecast by Country (2026-2031) & (K Units)
Table 62. Americas Performance Enhancing Drugs Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC Performance Enhancing Drugs Sales Forecast by Region (2026-2031) & (K Units)
Table 64. APAC Performance Enhancing Drugs Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe Performance Enhancing Drugs Sales Forecast by Country (2026-2031) & (K Units)
Table 66. Europe Performance Enhancing Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Performance Enhancing Drugs Sales Forecast by Country (2026-2031) & (K Units)
Table 68. Middle East & Africa Performance Enhancing Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global Performance Enhancing Drugs Sales Forecast by Type (2026-2031) & (K Units)
Table 70. Global Performance Enhancing Drugs Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global Performance Enhancing Drugs Sales Forecast by Application (2026-2031) & (K Units)
Table 72. Global Performance Enhancing Drugs Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Taj Pharmaceuticals Basic Information, Performance Enhancing Drugs Manufacturing Base, Sales Area and Its Competitors
Table 74. Taj Pharmaceuticals Performance Enhancing Drugs Product Portfolios and Specifications
Table 75. Taj Pharmaceuticals Performance Enhancing Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 76. Taj Pharmaceuticals Main Business
Table 77. Taj Pharmaceuticals Latest Developments
Table 78. Balkan Pharmaceuticals Basic Information, Performance Enhancing Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Balkan Pharmaceuticals Performance Enhancing Drugs Product Portfolios and Specifications
Table 80. Balkan Pharmaceuticals Performance Enhancing Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 81. Balkan Pharmaceuticals Main Business
Table 82. Balkan Pharmaceuticals Latest Developments
Table 83. Bayer Basic Information, Performance Enhancing Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Bayer Performance Enhancing Drugs Product Portfolios and Specifications
Table 85. Bayer Performance Enhancing Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 86. Bayer Main Business
Table 87. Bayer Latest Developments
Table 88. AstraZeneca Basic Information, Performance Enhancing Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. AstraZeneca Performance Enhancing Drugs Product Portfolios and Specifications
Table 90. AstraZeneca Performance Enhancing Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 91. AstraZeneca Main Business
Table 92. AstraZeneca Latest Developments
Table 93. Novo Nordisk Basic Information, Performance Enhancing Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Novo Nordisk Performance Enhancing Drugs Product Portfolios and Specifications
Table 95. Novo Nordisk Performance Enhancing Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 96. Novo Nordisk Main Business
Table 97. Novo Nordisk Latest Developments
Table 98. BrainAlert Basic Information, Performance Enhancing Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. BrainAlert Performance Enhancing Drugs Product Portfolios and Specifications
Table 100. BrainAlert Performance Enhancing Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 101. BrainAlert Main Business
Table 102. BrainAlert Latest Developments
Table 103. Douglas Laboratories Basic Information, Performance Enhancing Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Douglas Laboratories Performance Enhancing Drugs Product Portfolios and Specifications
Table 105. Douglas Laboratories Performance Enhancing Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 106. Douglas Laboratories Main Business
Table 107. Douglas Laboratories Latest Developments
Table 108. Onnit Labs Basic Information, Performance Enhancing Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. Onnit Labs Performance Enhancing Drugs Product Portfolios and Specifications
Table 110. Onnit Labs Performance Enhancing Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 111. Onnit Labs Main Business
Table 112. Onnit Labs Latest Developments
Table 113. Eli Lilly And Company Basic Information, Performance Enhancing Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. Eli Lilly And Company Performance Enhancing Drugs Product Portfolios and Specifications
Table 115. Eli Lilly And Company Performance Enhancing Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 116. Eli Lilly And Company Main Business
Table 117. Eli Lilly And Company Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Performance Enhancing Drugs
Figure 2. Performance Enhancing Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Performance Enhancing Drugs Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Performance Enhancing Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Performance Enhancing Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Performance Enhancing Drugs Sales Market Share by Country/Region (2024)
Figure 10. Performance Enhancing Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Pills
Figure 12. Product Picture of Injections
Figure 13. Product Picture of Patches
Figure 14. Global Performance Enhancing Drugs Sales Market Share by Type in 2025
Figure 15. Global Performance Enhancing Drugs Revenue Market Share by Type (2020-2025)
Figure 16. Performance Enhancing Drugs Consumed in Athletes
Figure 17. Global Performance Enhancing Drugs Market: Athletes (2020-2025) & (K Units)
Figure 18. Performance Enhancing Drugs Consumed in Students
Figure 19. Global Performance Enhancing Drugs Market: Students (2020-2025) & (K Units)
Figure 20. Performance Enhancing Drugs Consumed in Militaries
Figure 21. Global Performance Enhancing Drugs Market: Militaries (2020-2025) & (K Units)
Figure 22. Performance Enhancing Drugs Consumed in Others
Figure 23. Global Performance Enhancing Drugs Market: Others (2020-2025) & (K Units)
Figure 24. Global Performance Enhancing Drugs Sale Market Share by Application (2024)
Figure 25. Global Performance Enhancing Drugs Revenue Market Share by Application in 2025
Figure 26. Performance Enhancing Drugs Sales by Company in 2025 (K Units)
Figure 27. Global Performance Enhancing Drugs Sales Market Share by Company in 2025
Figure 28. Performance Enhancing Drugs Revenue by Company in 2025 ($ millions)
Figure 29. Global Performance Enhancing Drugs Revenue Market Share by Company in 2025
Figure 30. Global Performance Enhancing Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 31. Global Performance Enhancing Drugs Revenue Market Share by Geographic Region in 2025
Figure 32. Americas Performance Enhancing Drugs Sales 2020-2025 (K Units)
Figure 33. Americas Performance Enhancing Drugs Revenue 2020-2025 ($ millions)
Figure 34. APAC Performance Enhancing Drugs Sales 2020-2025 (K Units)
Figure 35. APAC Performance Enhancing Drugs Revenue 2020-2025 ($ millions)
Figure 36. Europe Performance Enhancing Drugs Sales 2020-2025 (K Units)
Figure 37. Europe Performance Enhancing Drugs Revenue 2020-2025 ($ millions)
Figure 38. Middle East & Africa Performance Enhancing Drugs Sales 2020-2025 (K Units)
Figure 39. Middle East & Africa Performance Enhancing Drugs Revenue 2020-2025 ($ millions)
Figure 40. Americas Performance Enhancing Drugs Sales Market Share by Country in 2025
Figure 41. Americas Performance Enhancing Drugs Revenue Market Share by Country (2020-2025)
Figure 42. Americas Performance Enhancing Drugs Sales Market Share by Type (2020-2025)
Figure 43. Americas Performance Enhancing Drugs Sales Market Share by Application (2020-2025)
Figure 44. United States Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 45. Canada Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 46. Mexico Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 47. Brazil Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 48. APAC Performance Enhancing Drugs Sales Market Share by Region in 2025
Figure 49. APAC Performance Enhancing Drugs Revenue Market Share by Region (2020-2025)
Figure 50. APAC Performance Enhancing Drugs Sales Market Share by Type (2020-2025)
Figure 51. APAC Performance Enhancing Drugs Sales Market Share by Application (2020-2025)
Figure 52. China Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. Japan Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. South Korea Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 55. Southeast Asia Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 56. India Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 57. Australia Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 58. China Taiwan Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 59. Europe Performance Enhancing Drugs Sales Market Share by Country in 2025
Figure 60. Europe Performance Enhancing Drugs Revenue Market Share by Country (2020-2025)
Figure 61. Europe Performance Enhancing Drugs Sales Market Share by Type (2020-2025)
Figure 62. Europe Performance Enhancing Drugs Sales Market Share by Application (2020-2025)
Figure 63. Germany Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. France Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 65. UK Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 66. Italy Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 67. Russia Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 68. Middle East & Africa Performance Enhancing Drugs Sales Market Share by Country (2020-2025)
Figure 69. Middle East & Africa Performance Enhancing Drugs Sales Market Share by Type (2020-2025)
Figure 70. Middle East & Africa Performance Enhancing Drugs Sales Market Share by Application (2020-2025)
Figure 71. Egypt Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72. South Africa Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 73. Israel Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 74. Turkey Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 75. GCC Countries Performance Enhancing Drugs Revenue Growth 2020-2025 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Performance Enhancing Drugs in 2025
Figure 77. Manufacturing Process Analysis of Performance Enhancing Drugs
Figure 78. Industry Chain Structure of Performance Enhancing Drugs
Figure 79. Channels of Distribution
Figure 80. Global Performance Enhancing Drugs Sales Market Forecast by Region (2026-2031)
Figure 81. Global Performance Enhancing Drugs Revenue Market Share Forecast by Region (2026-2031)
Figure 82. Global Performance Enhancing Drugs Sales Market Share Forecast by Type (2026-2031)
Figure 83. Global Performance Enhancing Drugs Revenue Market Share Forecast by Type (2026-2031)
Figure 84. Global Performance Enhancing Drugs Sales Market Share Forecast by Application (2026-2031)
Figure 85. Global Performance Enhancing Drugs Revenue Market Share Forecast by Application (2026-2031)